“So I look at the basal, I look at the pump, it's probably good drivers for us in '24, '25, but we've got multiple growth verticals here on this platform like I've said.”

In context

“to all the different pump manufacturers. I think this is a great opportunity for us. And I think it's good for patients. I think it's going to be good to have a different option especially for this patient population, where insulin delivery and the whole connected system is important, right? Recently, there was an independent third party study. I think this is the first time we've seen an independent head to head study that was published a few weeks ago, showing that Libre 3 is superior to the recently launched product from our competitor across a variety of different metrics, whether it's bias, whether it's MARD. So I look at that and I say, okay, through a pump company, and you're wanting to provide the best solution to users, that's an important aspect, especially for this segment. So I look at the basal, I look at the pump, it's probably good drivers for us in '24, '25, but we've got multiple growth verticals here on this platform like I've said. To your question on IQVIA, I think anybody who kind of follows Pharma and is more attuned to pharma knows that IQVIA doesn't pick up the entire market. So the pharmacy channel in the U.S. gets picked up by IQVIA, but there are other segments in the market that drive adoption that don't get picked up by IQVIA. So maybe that's what you're seeing. Operator: Our next question will come from Danielle Antalffy from UBS. Danielle Antalffy: Congrats on strong end to the year and strong guidance. Just, Robert, since the story seems to be very much about top line growth. I haven't heard you reference the Fab 5, one of my favorite analogies in a long time. So just wanted to -- and maybe I just missed it, but I just wanted to get an update on those 5 products or where you think you guys are in la”